Selecting a Dosage Form for Drug Delivery to the Lungs

Salt form screening (if applicable) is an important early step in inhalation dosage form selection. Approximately 50% of active pharmaceutical ingredients (APIs) in approved products are salt forms,1 and that proportion is slightly higher (approx. 60%) for APIs in approved inhalation products. For each type of formulation (e.g. solution versus suspension) or dosage form, it is conceivable that a different salt form will be most amenable for development. As with all pharmaceutical development, understanding the physical and chemical properties of the active pharmaceutical ingredient (API), and its different forms if applicable, is critical in defining the dosage form design space.

Spotlight

PHOENIX All-in-One

All-in-One: Our expertise and coverage for the success of manufacturer partners to provide manufacturer partners a unified approach to the European and all 26 local markets, the PHOENIX group has brought the service brand “All-in-One” into life. All-in-One grants a direct access for manufacturers to patients. With its eight focus areas from a Pan-European Preferred Partnerships, Healthcare Logistics, Business Intelligence, Patient Services to Supply Chain Optimization, Sales Support, Clinical Trial Supply Services and Services for Specialty Drugs, All-in-One has an unparalleled service to manufacturer partners throughout Europe. You do your core business – we care about the rest Our full-service offering enables manufacturers to focus on their core competencies – developing and successfully commercializing innovative products and solutions. We care about the rest. “All-in-One is more than just a collection of services, it is a unified approach to patients all over Europe”, says Stefan

OTHER WHITEPAPERS
news image

The Ultimate Guide to Pharmaceutical Quality Managemen

whitePaper | October 20, 2022

When the first Nokia and Motorola cell phones that were affordable and small enough to fit in your pocket hit the market, they not only changed how we viewed phone technology but how we communicated.

Read More
news image

Shifting to an Audience-Focused Product Marketing Strategy

whitePaper | February 24, 2023

The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Latest Evidence and Effects of Vitamin D3 (cholecalciferol)-Drug Interactions

whitePaper | October 15, 2022

Because vitamin D receptors are present in most cells in the body, its active form has potent effects on the growth and differentiation of many types of cells, meaning that vitamin D

Read More
news image

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More

Spotlight

PHOENIX All-in-One

All-in-One: Our expertise and coverage for the success of manufacturer partners to provide manufacturer partners a unified approach to the European and all 26 local markets, the PHOENIX group has brought the service brand “All-in-One” into life. All-in-One grants a direct access for manufacturers to patients. With its eight focus areas from a Pan-European Preferred Partnerships, Healthcare Logistics, Business Intelligence, Patient Services to Supply Chain Optimization, Sales Support, Clinical Trial Supply Services and Services for Specialty Drugs, All-in-One has an unparalleled service to manufacturer partners throughout Europe. You do your core business – we care about the rest Our full-service offering enables manufacturers to focus on their core competencies – developing and successfully commercializing innovative products and solutions. We care about the rest. “All-in-One is more than just a collection of services, it is a unified approach to patients all over Europe”, says Stefan

Events